Search Results
Your search for The ASCO Post matches 376 pages
Showing 101 - 150
A Discussion About CAR T-Cell Therapy for Multiple Myeloma and Lymphoma
Dr. Armitage discusses the role of CAR T-cell therapy in the management of multiple myeloma and lymphoma in a conversation with his colleagues Dr. Holstein and Dr. Lunning.
A Case of Diffuse Large B-Cell Lymphoma
Dr. Armitage presents a case and asks Dr. Lunning to describe how he would treat this patient. The patient is a 52-year-old man who found a neck mass himself. He went to his doctor and was prescribed antibiotics. When the antibiotics failed to impact the mass, a biopsy was performed and a diagnosis ...
A Case of Relapsed/Refractory Hodgkin Lymphoma
Dr. Armitage presents a case and asks Dr. Lunning to describe how he would treat this patient. The patient is a 25-year-old man with a diagnosis of stage III nodular sclerosing Hodgkin lymphoma. His disease went into complete remission when the patient was treated with ABVD and he was well. One...
Jennifer Crombie, MD, on Relapsed or Refractory CLL/SLL: Results From a Phase I Trial of Duvelisib and Venetoclax
Jennifer Crombie, MD, of Dana-Farber Cancer Institute, discusses early study results which showed that duvelisib plus venetoclax showed activity in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, with no dose-limiting toxicities observed (Abstract 1763).
Catherine M. Diefenbach, MD, on Follicular Lymphoma: Polatuzumab Vedotin Plus Obinutuzumab/Lenalidomide
Catherine M. Diefenbach, MD, of the Perlmutter Cancer Center at NYU Langone, discusses a primary analysis of a phase Ib/II trial showing that the novel triplet combination of polatuzumab vedotin plus obinutuzumab/lenalidomide is safe and effective, with high complete response rates seen in a...
Loretta J. Nastoupil, MD, on Follicular Lymphoma: Trial Results With Obinutuzumab/Lenalidomide
Loretta J. Nastoupil, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II study findings that showed obinutuzumab in combination with lenalidomide for patients with previously untreated, high tumor burden follicular lymphoma was associated with improved outcomes (Abstract...
Richard I. Fisher, MD, on Follicular Lymphoma: Optimizing First-Line Therapy
Richard I. Fisher, MD, of Fox Chase Cancer Center, discusses the improvement in survival for patients with follicular lymphoma, new targeted biologic agents providing alternative treatments, and chemoimmunotherapy (a standard in many cases).
Michael J. LaRiviere, MD, on Non-Hodgkin Lymphoma: Induction Radiation Before CAR T-Cell Therapy for Resistant Disease
Michael J. LaRiviere, MD, of the University of Pennsylvania, discusses the safety and efficacy of an alternate radiation-based approach to using cytotoxic chemotherapy alone in preparation for CAR T-cell treatment (Abstract 135).
FDA Pipeline: Priority Reviews in Prostate Cancer, Mantle Cell Lymphoma
This week, the U.S. Food and Drug Administration (FDA) accepted new drug applications for enzalutamide in metastatic hormone-sensitive prostate cancer and zanubrutinib in relapsed or refractory mantle cell lymphoma, and granted both applications Priority Review. Priority Review for Enzalutamide in ...
Can Treatment With Antibiotics Inhibit Malignant T Cells in Cutaneous T-Cell Lymphoma?
Many patients with cutaneous T-cell lymphoma contract Staphylococcus aureus infections in the skin. In a new study, researchers have shown that aggressive treatment with antibiotics for patients with these infections not only inhibits the staphylococcal bacteria—but also the cancer...
Germline BRCA2 Mutations and Risk of Pediatric or Adolescent Lymphoma
A research letter published by Wang et al in JAMA Oncology has found that inherited mutations in the BRCA2 gene are linked to an increased risk for non-Hodgkin lymphoma in children and adolescents. “The BRCA family of genes are known to be linked to risk for breast and...
FDA Requests Manufacturer Recall of Some Textured Breast Implants
Today, the U.S. Food and Drug Administration (FDA) requested that Allergan, the manufacturer of a specific type of textured breast implant, recall specific models of its textured implants from the U.S. market due to the risk of breast implant–associated anaplastic large cell lymphoma (ALCL)....
FDA Approves Rituximab Biosimilar for Non-Hodgkin Lymphoma, CLL, and Autoimmune Conditions
Today, the U.S. Food and Drug Administration (FDA) approved rituximab-pvvr (Ruxience), a biosimilar to rituximab (Rituxan), for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis and microscopic polyangiitis....
FDA Pipeline: Designations and Applications Granted in Lymphoma, Small Cell Lung Cancer, Multiple Myeloma, and More
Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to a phospholipid-drug conjugate in diffuse large B-cell lymphoma; granted Orphan Drug designation to an immunotherapy for small cell lung cancer (SCLC); accepted supplemental biologics license applications (sBLAs) ...
15-ICML: Adding Lenalidomide to R-CHOP in Newly Diagnosed DLBCL
In the phase II ECOG-ACRIN 1412 trial, presented by Nowakowski et al at the 15th International Conference on Malignant Lymphoma (ICML; Abstract 006), researchers sought to compare the addition of lenalidomide to R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) vs...
15-ICML: Can Serum Biomarkers Provide Prognostic Information in Relapsed Mantle Cell Lymphoma?
Data presented by Lokhande et al at the 15th International Conference on Malignant Lymphoma (ICML; Abstract 360) focused on noninvasive strategies to guide patient stratification for relapsed mantle cell lymphoma. Researchers used an antibody-based platform to identify serum proteins in patients...
FDA Pipeline: Applications Accepted in Gynecologic Cancers, Targeted Therapies
Recently, the U.S. Food and Drug Administration (FDA) accepted a new drug application for niraparib in the treatment of certain pretreated gynecologic cancers; granted Fast Track designation to a T-cell product; accepted investigational new drug applications for a myelopreservation agent and an...
15-ICML: Final Data From ALCANZA: Brentuximab Vedotin for CD30-Positive CTCL
Final analyses from the ALCANZA study, a phase III trial investigating brentuximab vedotin vs physician’s choice for the treatment of CD30-positive cutaneous T-cell lymphoma (CTCL), were presented by Horwitz et al at the 15th International Conference on Malignant Lymphoma (ICML; Abstract...
15-ICML: ROBUST Trial Examines Efficacy of Lenalidomide/R-CHOP in Previously Untreated ABC-Type DLBCL
The ROBUST trial compared the addition of lenalidomide to R-CHOP (rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone) vs placebo/R-CHOP in previously untreated, prospectively selected, CD20-positive patients with activated B-cell–like (ABC)-type diffuse large B-cell...
15-ICML: Genotyping of ctDNA in Classical Hodgkin Lymphoma
An abstract presented by Camus et al at the 15th International Conference on Malignant Lymphoma (ICML; Abstract 138) found that targeted genotyping of circulating tumor DNA (ctDNA) in classical Hodgkin lymphoma at diagnosis “may help to assess early treatment response in complement to...
15-ICML: Post Hoc Analysis of MAVORIC Study: Mogamulizumab in Patients With Previously Treated Cutaneous T-Cell Lymphoma
The MAVORIC study—presented by Scarisbrick et al at the 15th International Conference on Malignant Lymphoma (ICML; Abstract 034)—examined the efficacy of mogamulizumab, a monoclonal antibody that targets the CC chemokine receptor 4 (CCR4), in patients with previously treated mycosis...
15-ICML: Identifying Genetic Alterations Associated With Relapse in DLBCL
In an abstract presented by Rushton et al at the 15th International Conference on Malignant Lymphoma (ICML; Abstract 004), researchers found that patients with diffuse large B-cell lymphoma (DLBCL) with specific mutations in relapse-enriched genes may be at a higher risk of treatment failure. The...
Cytoreductive Surgery for Primary Central Nervous System Lymphoma
Through a systematic review of published studies, researchers report they have identified a distinct subtype of primary central nervous system (PCNS) lymphoma that should be considered for surgical removal, suggesting a major shift in how this type of tumor is evaluated and managed. These findings...
FDA Approves Polatuzumab Vedotin-piiq in Combination With Bendamustine and a Rituximab Product for DLBCL
On June 10, the U.S. Food and Drug Administration (FDA) granted accelerated approval to polatuzumab vedotin-piiq (Polivy), a CD79b-directed antibody-drug conjugate, in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma...
FDA Pipeline: Reviews and Designations in Multiple Myeloma, Lymphoma, Prostate Cancer
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review for daratumumab in combination with a triplet therapy in multiple myeloma, Breakthrough Therapy designation to copanlisib for marginal zone lymphoma, and Fast Track designation for ARV-110 in metastatic...
2019 ASCO: Rituximab, Lenalidomide, and Ibrutinib Prior to Chemotherapy in DLBCL
Results of the phase II Smart Start trial revealed that combination targeted therapy consisting of rituximab, lenalidomide, and ibrutinib had an 84.6% overall response rate (ORR) and 38.5% complete response rate (CRR) when given prior to any chemotherapy for newly diagnosed patients with a...
Jason Westin, MD, on Diffuse Large B-Cell Lymphoma: Rituximab, Lenalidomide, and Ibrutinib Prior to Chemotherapy
Jason Westin, MD, of The University of Texas MD Anderson Cancer Center, discusses findings of the Smart Start study on the chemotherapy-free combination of rituximab, lenalidomide, and ibrutinib in newly diagnosed diffuse large B-cell lymphoma (Abstract 7508).
William G. Wierda, MD, PhD, on Immunotherapy for Relapsed/Refractory CLL/SLL: Results From TRANSCEND CLL 004
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the TRANSCEND CLL 004 trial, which studied the use of an experimental CD19-directed CAR T-cell product in heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (Abstract ...
FDA Approves Lenalidomide in Combination for Previously Treated Follicular and Marginal Zone Lymphomas
Today, the U.S. Food and Drug Administration (FDA) approved lenalidomide (Revlimid) in combination with a rituximab product for previously treated follicular and marginal zone lymphoma. AUGMENT and MAGNIFY Trials Approval was based on two clinical trials: AUGMENT and MAGNIFY. In AUGMENT, 358...
FDA Approves Chemotherapy-Free Regimen, Venetoclax Plus Obinutuzumab, as First-Line Treatment for CLL/SLL
The U.S. Food and Drug Administration (FDA) has approved venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The approval is based on the results of the...
ESTRO 38: Radiotherapy After ABVD May Improve Survival in Advanced Hodgkin Lymphoma
Patients with advanced Hodgkin lymphoma with bulky lesions at the time of diagnosis may benefit from radiotherapy after chemotherapy, according to late-breaking results presented by Ricardi et al at ESTRO 38, the annual congress of the European Society for Radiotherapy & Oncology...
Frederick L. Locke, MD, on Innovative CAR-T Cell Therapies: The Patient Experience
Frederick L. Locke, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses recent approvals of chimeric antigen receptor T-cell therapies in leukemia and lymphoma, and how clinicians are using infrastructure, navigation, and early referrals to maximize response and minimize...
FDA Pipeline: Updates on Treatments for Cervical Cancer, Myelofibrosis, Chemotherapy-Induced Nausea and Vomiting, and More
The FDA recently issued announcements on a Fast Track designation, a Priority Review, two supplemental new drug applications, an investigational new drug application, and a marketing clearance. The agency also released a safety communication on cancer-related surgery. Fast Track Designation for...
FDA Pipeline: Priority Reviews in Solid Tumors and Lymphoma; Plus an sNDA in Acute Myeloid Leukemia
Over the past week, the U.S. Food and Drug Administration (FDA) granted multiple Priority Reviews and accepted a supplemental new drug application: Priority Review for Entrectinib in NTRK Fusion–Positive Solid Tumors and Metastatic, ROS1-Positive NSCLC This week, the FDA accepted new drug...
Cutaneous T-Cell Lymphoma: Can Genetic Polymorphisms Help Select Patients for Treatment With Bexarotene?
Bexarotene is a retinoid approved for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have not responded to at least one previous treatment regimen. Hypertrigylceridemia is the most frequent adverse event related to treatment with bexarotene in CTCL. Even with prophylactic...
FDA Pipeline: Treatments for Tenosynovial Giant Cell Tumor and Pancreatic Cancer, Plus a Statement on Breast Implant–Associated Lymphoma
The U.S. Food and Drug Administration (FDA) recently granted the following designations and applications and also issued a statement: Priority Review for Pexidartinib in Tenosynovial Giant Cell Tumor The FDA has accepted a new drug application (NDA) and granted Priority Review for pexidartinib...
FDA Pipeline: Updates on Treatments in NSCLC and Lymphomas, Plus New Dosimetry Software
The U.S. Food and Drug Administration (FDA) recently granted the following application, designations, and clearance: sBLA for Atezolizumab Plus Chemotherapy for First-Line Treatment of Metastatic, Nonsquamous NSCLC On January 17, the FDA accepted a supplemental biologics license application...
FDA Approves Ibrutinib in Combination With Obinutuzumab in Treatment-Naive CLL/SLL
Today, the U.S. Food and Drug Administration (FDA) approved ibrutinib (Imbruvica), a Bruton's tyrosine kinase inhibitor, in combination with obinutuzumab in treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This is the first approval of a...
High Long-Term Risk of Solid Cancers in Survivors of Childhood Hodgkin Lymphoma
A new study may bolster existing evidence that survivors of childhood Hodgkin lymphoma face an elevated risk of developing various types of solid tumors many years later. The study showed that certain subgroups of patients have an especially high risk. Published by Holmqvist et al in the journal...
FDA Pipeline: New Priority Reviews, Designations, and Clearances, Plus Statements on Genetic Testing and Class Labeling
The U.S. Food and Drug Administration (FDA) recently issued the following new approvals and designations: Priority Review for Atezolizumab in Combination With Chemotherapy for the Initial Treatment of Extensive-Stage SCLC The FDA accepted a supplemental biologics license application...
Laurie H. Sehn, MD, MPH, on DLBCL: Trial Results on the Prognostic Significance of MYC
Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Centre for Lymphoid Cancer, discusses a study by the Lunenburg Lymphoma Biomarker Consortium that confirmed previous reports on the negative prognostic impact of an underlying MYC-translocation for both progression-free and overall survival in ...
ASH 2018: CAR.CD30 T-Cell Therapy in Relapsed or Refractory CD30-Positive Lymphomas
At the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition, Grover et al presented preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker (Abstract 681). Data...
Steven M. Horwitz, MD, on PTCL: Results From the ECHELON-2 Trial
Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III findings on brentuximab vedotin and CHP vs CHOP in the front-line treatment of patients with CD30-positive peripheral T-cell lymphomas (Abstract 997).
Steven M. Horwitz, MD, on PTCL and CTCL: Trial Results on Cerdulatinib
Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase IIa study findings on the novel SYK/JAK inhibitor cerdulatinib for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma (Abstract 1001).
Anas Younes, MD, on DLBCL: Phase III Trial Results
Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, discusses trial findings on ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in people with previously untreated non–germinal center B-cell–like diffuse large B-cell lymphoma (Abstract 784).
Julie Vose, MD, MBA, and Loretta J. Nastoupil, MD, on Large B-Cell Lymphoma: Real-World Experience With CAR T-Cell Therapy
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Loretta J. Nastoupil, MD, of The University of Texas MD Anderson Cancer Center, discuss findings from a multicenter study of axicabtagene ciloleucel CD19 CAR T-cell therapy for relapsed or refractory aggressive B-cell lymphoma...
Julie Vose, MD, MBA, and Merav Bar, MD, on CAR T-Cell Therapy: Late Effects of CD19-Targeted Treatment
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Merav Bar, MD, of the Fred Hutchinson Cancer Research Center, discuss study findings on the long-term effects in people with relapsed or refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia who received CD19-targeted ...
John P. Leonard, MD, on NHL: Results From the AUGMENT Trial
John P. Leonard, MD, of Weill Cornell Medicine/Cornell University, discusses phase III findings on lenalidomide plus rituximab vs rituximab plus placebo for people with relapsed or refractory indolent non-Hodgkin lymphoma (Abstract 445).
ASH 2018: Update of ZUMA-1: Axicabtagene Ciloleucel in DLBCL
A follow-up analysis of patients enrolled in the multicenter ZUMA-1 trial for diffuse large B-cell lymphoma (DLBCL) showed axicabtagene ciloleucel can induce durable responses, yield a median overall survival of more than 2 years, and has a manageable long-term safety profile. Axicabtagene...
Gilles A. Salles, MD, PhD, on DLBCL: Results From the L-Mind Treatment Trial
Gilles A. Salles, MD, PhD, of Centre Hospitalier Lyon Sud, discusses trial findings on the monoclonal antibody MOR208 combined with lenalidomide in people with relapsed or refractory diffuse large B-cell lymphoma (Abstract 227).
